Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan C Buckner

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2010
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risksJann N Sarkaria, Eva Galanis, Wenting Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examinationPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trialPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDHJ Gregory Cairncross, Meihua Wang, Robert B Jenkins, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2010
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074Joon H Uhm, Karla V Ballman, Wenting Wu, et al.
Neuro-Oncology|February 1, 2020
Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade gliomaWilliam G Breen, S Keith Anderson, Xiomara W Carrero, et al.
Cancer|January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2010
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risksJann N Sarkaria, Eva Galanis, Wenting Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examinationPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Neuro-Oncology|June 6, 2019
Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG)Kurt A Jaeckle, S K Anderson, Erin L Twohy, et al.
International Journal of Radiation Oncology, Biology, Physics|March 6, 2004
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trialPaul D Brown, Jan C Buckner, Judith R O'Fallon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDHJ Gregory Cairncross, Meihua Wang, Robert B Jenkins, et al.
International Journal of Radiation Oncology, Biology, Physics|June 1, 2010
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074Joon H Uhm, Karla V Ballman, Wenting Wu, et al.
Neuro-Oncology|February 1, 2020
Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade gliomaWilliam G Breen, S Keith Anderson, Xiomara W Carrero, et al.
Cancer|January 10, 2018
Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572David Schiff, Kurt A Jaeckle, S Keith Anderson, et al.
Cancer|July 11, 2019
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872Evanthia Galanis, S Keith Anderson, Erin L Twohy, et al.
Neuro-Oncology Advances|June 6, 2022
Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance)Evanthia Galanis, S Keith Anderson, Erin Twohy, et al.
Pageof 14